Cyclica Inc

Cyclica Launches Ligand Design™, a Powerful Multi-Targeted Drug Design Technology at Collision Conference Toronto

This post was adapted from its original source on Business Wire and can be viewed here.

TORONTO, CANADA – (May 22, 2019) – Cyclica, a leading biotechnology company that commercialized Ligand Express® announced its novel, first-in-class drug design technology, Ligand DesignTM on stage at the Collision Conference in Toronto. This revolutionary platform empowers scientists in the pharmaceutical industry to generate novel drug-like compounds by combining powerful methods for molecule generation, ADMET prediction, and high-throughput ligand-protein interaction prediction.

“Together, with Ligand Design and Ligand Express we will move away from the classical computational drug discovery paradigm, and accelerate drug discovery by designing drugs for patients, not proteins.”

— John Conway, Adviser at Cyclica, and Global Head, Data Science and AI IT at AstraZeneca.

Classical computational drug design approaches, like virtual screening, focus on a single protein target. These approaches do not holistically consider a drug’s polypharmacology, the phenomenon of one drug acting on multiple proteins in the body, or a drug’s pharmacokinetic properties, which describes how a drug is absorbed and processed by the body. Unlike single target approaches, Ligand Design focuses on a drug’s polypharmacology and explores synthetically accessible chemical space to de novo design small molecules against a collection of targets and anti-targets, while simultaneously selecting for physicochemical and ADMET properties. Ligand Design has the ability to transform research and discovery processes, and augment the capabilities of scientists to rapidly design drugs with greater precision and efficacy. The platform has been used by leading pharmaceutical companies, biotech companies, and academia globally, and is showing promising results in drug discovery. To date, several novel agents have been synthesized and tested successfully for activity in multiple disease areas.

“I believe that the Cyclica team is on the forefront of innovation in drug discovery. Together with Ligand Express, their new Ligand Design technology will reshape and enhance how scientists conduct their research faster and with higher quality,” said John Conway, Adviser at Cyclica, and Global Head, Data Science and AI IT at AstraZeneca. “At the end of the day, it’s all about making faster and more informed decisions, and their drug discovery platform allows scientists to do just that.”

“Our vision is to reduce the time of drug discovery from 7 years to 2 years, and to get the best molecules in the hands of patients faster. We believe this can be accomplished by empowering experimental scientists in pharma with a holistic and integrated in silico workflow that combines computational biophysics and machine learning,” said Naheed Kurji, President and CEO at Cyclica. “Together, with Ligand Design and Ligand Express we will move away from the classical computational approaches, and accelerate drug discovery by designing drugs for patients, not proteins.”

About Cyclica
Cyclica is a Toronto-based, globally recognized biotechnology company that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. Cyclica provides the pharmaceutical industry with an integrated, holistic, and end-to-end enabling platform focused on polypharmacology that enhances how scientists design, screen, and personalize medicines for patients while minimizing off-target side effects. By doing more with artificial intelligence, Cyclica aims to revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process, and develop medicines with greater precision.

Media Inquiries:
Naheed Kurji
President and CEO
Cyclica Inc